Sciclone Pharmaceuticals Inc (SCLN) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
950 TOWER LANE FOSTER CITY, CA 94404-2125 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2017 MRQ | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 134,395 | 101,403 | 86,303 | 85,803 | 84,228 | |||
| Cash and cash equivalent | 134,395 | 101,403 | 86,228 | 85,803 | 84,228 | |||
| Short-term investments | 75 | |||||||
| Restricted cash and investments | 75 | 2,759 | ||||||
| Receivables | 41,510 | 39,363 | 40,268 | 40,008 | 38,109 | |||
| Inventory, net of allowances, customer advances and progress billings | 16,587 | 10,976 | 10,703 | 15,238 | 10,424 | |||
| Inventory | 16,587 | 10,976 | 10,703 | 15,238 | 10,424 | |||
| Prepaid expense and other current assets | ✕ | ✕ | ✕ | ✕ | 2,287 | 1,809 | ||
| Deferred tax assets | 299 | 326 | ||||||
| Other undisclosed current assets | 3,241 | 16,480 | 2,597 | |||||
| Total current assets: | 195,733 | 168,521 | 140,197 | 143,411 | 137,329 | |||
| Noncurrent Assets | ||||||||
| Property, plant and equipment | 2,002 | 2,651 | 1,848 | 843 | 1,377 | |||
| Long-term investments and receivables | 4,750 | |||||||
| Accounts and financing receivable, after allowance for credit loss | 4,750 | |||||||
| Intangible assets, net (including goodwill) | 30,838 | 32,979 | 34,521 | 35,357 | 34,313 | |||
| Goodwill | 30,838 | 32,979 | 34,521 | 35,357 | 34,313 | |||
| Other noncurrent assets | 12,531 | 12,468 | ✕ | |||||
| Other undisclosed noncurrent assets | 794 | 515 | 616 | 1,052 | ||||
| Total noncurrent assets: | 46,165 | 48,098 | 41,634 | 36,816 | 36,742 | |||
| TOTAL ASSETS: | 241,898 | 216,619 | 181,831 | 180,227 | 174,071 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 26,441 | 36,646 | 35,231 | 33,683 | 33,624 | |||
| Taxes payable | 5,208 | 5,029 | 4,410 | |||||
| Employee-related liabilities | 4,176 | |||||||
| Accounts payable | 3,645 | 4,495 | 5,311 | 7,190 | 7,787 | |||
| Accrued liabilities | 22,796 | 32,151 | 20,536 | 21,464 | 21,427 | |||
| Debt | 1,651 | 1,445 | ||||||
| Deferred revenue and credits | 174 | 596 | 2,915 | |||||
| Deferred tax liabilities | 368 | 153 | ||||||
| Total current liabilities: | 26,441 | 36,820 | 35,827 | 38,617 | 35,222 | |||
| Noncurrent Liabilities | ||||||||
| Liabilities, other than long-term debt | 92 | 87 | ||||||
| Other liabilities | 92 | 87 | ||||||
| Total noncurrent liabilities: | 92 | 87 | ||||||
| Total liabilities: | 26,533 | 36,907 | 35,827 | 38,617 | 35,222 | |||
| Equity | ||||||||
| Equity, attributable to parent | 215,365 | 179,712 | 155,274 | 146,595 | 143,022 | |||
| Common stock | 51 | 50 | 50 | 52 | 54 | |||
| Additional paid in capital | 304,599 | 296,086 | 287,108 | 278,327 | 274,387 | |||
| Accumulated other comprehensive income (loss) | (1,520) | 2,070 | 3,264 | 4,176 | 2,988 | |||
| Accumulated deficit | (87,765) | (118,494) | (135,148) | (135,960) | (134,407) | |||
| Total equity: | 215,365 | 179,712 | 155,274 | 146,595 | 143,022 | |||
| Other undisclosed liabilities and equity | (9,270) | (4,985) | (4,173) | |||||
| TOTAL LIABILITIES AND EQUITY: | 241,898 | 216,619 | 181,831 | 180,227 | 174,071 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2017 TTM | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 160,096 | 157,257 | 134,790 | 127,058 | 156,269 | ||
| Revenue, net | 155,937 | 154,329 | 131,973 | 99,414 | 123,171 | ||
| Cost of revenue | (36,990) | (44,013) | (1,574) | ||||
| Cost of product and service sold | (34) | (1,574) | |||||
| Gross profit: | 123,106 | 113,244 | 133,216 | 127,058 | 156,269 | ||
| Operating expenses | (89,871) | (83,333) | (72,101) | (92,898) | (96,318) | ||
| Other undisclosed operating loss | (35,131) | (23,731) | (53,541) | ||||
| Operating income: | 33,235 | 29,911 | 25,984 | 10,429 | 6,410 | ||
| Nonoperating income (expense) | 898 | 359 | 393 | 2,777 | (42) | ||
| Loss, foreign currency transaction, before tax | (2,200) | (400) | |||||
| Other nonoperating income (expense) | (164) | (510) | 280 | 2,795 | (42) | ||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | (96) | ||||||
| Income from continuing operations before income taxes: | 34,133 | 30,270 | 26,377 | 13,206 | 6,272 | ||
| Income tax expense (benefit) | (3,404) | (807) | (1,169) | (2,242) | 3,348 | ||
| Income from continuing operations: | 30,729 | 29,463 | 25,208 | 10,964 | 9,620 | ||
| Income before gain (loss) on sale of properties: | 30,729 | 29,463 | 25,208 | 10,964 | 9,620 | ||
| Net income available to common stockholders, diluted: | 30,729 | 29,463 | 25,208 | 10,964 | 9,620 | ||
Comprehensive Income ($ in thousands)
| 6/30/2017 TTM | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|---|
| Net income: | 30,729 | 29,463 | 25,208 | 10,964 | 9,620 | ||
| Other comprehensive income (loss) | (912) | 1,188 | 644 | ||||
| Comprehensive income: | 30,729 | 29,463 | 24,296 | 12,152 | 10,264 | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (3,590) | (1,194) | |||||
| Comprehensive income, net of tax, attributable to parent: | 27,139 | 28,269 | 24,296 | 12,152 | 10,264 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.